Scott has more than seventeen years of intellectual property law experience. He works with commercial entities and academic institutions to protect their inventions and develop strategies to maximize the value of their intellectual property assets. Scott has guided the intellectual property strategy of early-stage companies throughout their development, from start-up through VC financing rounds to IPO. The comma makes the “and IPO. He also works with multi-national biotechnology and pharmaceutical companies.
Scott started his patent law career at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, where he worked as a technical specialist, student associate, and associate. After that he worked at Wilson, Sonsini, Goodrich & Rosati, PC, before joining Sal to form the predecessor firm to Arrigo, Lee & Guttman LLP. Prior to his career in patent law, Scott earned his Ph.D. in Molecular, Cellular & Developmental Biology from Harvard University and did post-doctoral work at the University of California, San Francisco.
Scott’s practice focuses on patent application preparation and prosecution, strategic patent counseling and worldwide portfolio development, due diligence investigations, and non-infringement and invalidity opinions. Scott also has significant experience in ex parte and inter parte proceedings before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office and has represented clients in appeals before the U.S. Court of Appeals for the Federal Circuit.
Scott has worked with diverse technologies, including stem cells, biologics, small-molecule pharmaceuticals, diagnostics, synthetic biology, dietary supplements, and microfluidics. He also advises clients and speaks on the interaction of FDA law and patent law.
- District of Columbia
- U.S. Patent and Trademark Office
- Georgetown University Law Center, J.D., 2005
- Harvard University, Ph.D., Department of Molecular, Cellular and Developmental Biology, 1999
- University of Chicago, B.A., Biology (with honors), 1993
- Co-developer and co-instructor, “Creating and Enforcing FDA Orange Book-Listable Small Molecule U.S. Patents,” Patent Resources Group Advanced Course, 2008-2009.
- Coauthor. “The Evolution of Intent: A Review of Patent Law Cases Invoking the Doctrine of Inequitable Conduct from Precision to Exergen,” University of Dayton Law Review, 2010.
- Coauthor, “Nonobviousness in the U.S. Post-KSR for Innovative Drug Companies,” University of Dayton Law Review, 2009.
|Scott M. K. Lee can be reached via e-mail at: firstname.lastname@example.org
Scott M. K. Lee can be contacted via his direct line at 202.684.7344